Abstract
The cornerstone of pharmacotherapeutic treatment for age-related macular degeneration (AMD) is photodynamic therapy with verteporfin. The recently approved pegaptanib sodium, which targets vascular endothelial growth factor (VEGF), reduces vision loss in AMD when given by intravitreal injection every 6 weeks. The early promise of monotherapy with the corticosteroid triamcinolone acetonide has yet to be borne out in larger clinical trials, but outcomes may be improved when it is used in combination with verteporfin therapy. The angiostatic cortisone anecortave acetate was recently reported to have failed to meet the primary efficacy criterion in two large, placebo-controlled trials, and its clinical utility is uncertain. Other potential treatments with varying mechanisms of action are currently under investigation. To date, no agent has been shown to significantly restore lost vision in patients with AMD. Future treatment strategies are likely to include a combination of treatments to better manage AMD-associated choroidal neovascularisation and preserve patients’ visual acuity.
References
1.
Attebo K, Mitchell P, Smith W: Visual acuity and the causes of visual loss in Australia: The Blue Mountains Eye Study. Ophthalmology 1996;103:357–364.
2.
Klein R, Wang Q, Klein B, Moss S, Meuer S: The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182–191.
3.
Mitchell P, Smith W, Attebo K, Wang J: Prevalence of age-related maculopathy in Australia: The Blue Mountains Eye Study. Ophthalmology 1995;102:1450–1460.
4.
VanNewkirk MR, Weih L, McCarthy CA, Taylor H: Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: The Visual Impairment Project. Ophthalmology 2001;108:960–967.
5.
Vingerling JR, Dielmans I, Hofman A, Grobbee D, Hijmering M, Kramer C, de Jong P: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205–210.
6.
Friedman DS, O’Colmain BJ, Munoz B, Tomany S, McCarty C, de Jong P, Nemesure B, Mitchell P, Kempen J: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564–572.
7.
Thylefors B: A global initiative for the elimination of avoidable blindness. Am J Ophthalmol 1998;125:90–93.
8.
Evans J: Studies on Medical and Population Subjects No 57. London, HMSO, 1995.
9.
Bressler NM: Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract 2002;15:142–152.
10.
Ferris FL, Fine SL, Hyman LA: Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640–1642.
11.
Engerman RL, Pfaffenbach D, Davis MD: Cell turnover of capillaries. Lab Invest 1967;17:738–743.
12.
Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677–684.
13.
Aiello LP: Vascular endothelial growth factor: 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci 1997;38:1647–1652.
14.
Das A, McGuire PG: Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003;22:721–748.
15.
Schmidt-Erfuth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann G: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473–4480.
16.
Holz FG, Pauleikhoff R, Klein R, Bird AC: Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 2004;137:504–510.
17.
Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy: five-year results from randomised clinical trials. Arch Ophthalmol 1991;109:1109–1114.
18.
Macular Photocoagulation Study Group: Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242–1257.
19.
Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL: Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 1988;106:1537–1542.
20.
Soubrane G, Coscas G, Francais C, Koenig F: Occult subretinal new vessels in age-related macular degeneration: natural history and early laser treatment. Ophthalmology 1990;97:649–657.
21.
Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD: Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050–1058.
22.
Mitchell J, Wolffsohn JS, Woodcaock A, Anderson SJ, McMillan CV, Ffytche T: Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health Qual Life Outcomes 2005;3:25.
23.
Berdeaux GH, Nordmann JP, Colin E, Arnould B: Vision-related quality of life in patients suffering from age-related macular degeneration. Am J Ophthalmol 2005;139:271–279.
24.
Cahill MT, Banks AD, Stinnett SS, Toth CA: Vision-related quality of life in patients with bilateral severe age-related macular degeneration. Ophthalmology 2005;112:152–158.
25.
Chopda A, Chakravarthy U, Verma D: Age-related macular degeneration. Br J Cancer 2003;326:485–488.
26.
Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomised clinical trial. Arch Ophthalmol 1991;109:1220–1231.
27.
Macular Photocoagulation Study Group: Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994;112:480–488.
28.
Freund FL, Yannuzzi L, Sorenson JA: Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993;115:786–791.
29.
Macular Photocoagulation Study Group: Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986;104:503–512.
30.
Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomised clinical trial. Arch Ophthalmol 1991;109:1232–1241.
31.
Schmidt-Erfuth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R: Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953–1961.
32.
Schmidt-Erfuth U, Hasan T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195–214.
33.
Bressler N, Gills J: Age-related macular degeneration. BMJ 2000;321:1425–1427.
34.
Gragoudas ES, Amadis AP, Cunninham ETJ, Feinsod M, Guyer DR; The VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.
35.
D’Amico D; VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group: VEGF Inhibition Study in Ocular Neovascularization (VISION): second-year efficacy data (abstract 2309). Assoc Res Vision Ophthalmol annu meet, 2005.
36.
Schmidt-Erfurth U, Miller JW, Sickenberg M, et al: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1177–1187.
37.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomised clinical trials. Arch Ophthalmol 1999;117:1329–1345.
38.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials – TAP report 2. Arch Ophthalmol 2001;119:198–207.
39.
Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomised clinical trial including lesions with occult with no classic choroidal neovascularization – Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541–560.
40.
Visudyne in Minimally Classic Choroidal Neovascularization Study Group: Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomised clinical trial. Arch Ophthalmol 2005;123:448–457.
41.
Blinder KJ, Bradley S, Bressler NM, et al: Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No 1. Am J Ophthalmol 2003;136:407–418.
42.
Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators: Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6–18.
43.
Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: 4-year results of an open-label extension of two clinical trials – TAP report No 7 (letter). Arch Ophthalmol 2005;123:1283–1285.
44.
Bressler NM; the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials. Arch Ophthalmol 2001;119:198–207.
45.
Blumenkranz MS, Bressler NM, Bressler SB, et al: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: 3-year results of an open-label extension of two randomised clinical trials – TAP report No 5. Arch Ophthalmol 2002;120:1307–1314.
46.
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomised clinical trials – Treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report No 4. Retina 2004;24:1–12.
47.
Armbrecht AM, Aspinall PA, Dhillon B: A prospective study of visual function and quality of life following PDT in patients with wet age-related macular degeneration. Br J Ophthalmol 2004;88:1270–1273.
48.
Krummenauer F, Braun M, Dick HB: Clinical outcome and subjective quality of life after photodynamic therapy in patients with age-related macular degeneration. Eur J Ophthalmol 2005;15:74–80.
49.
Smith DH, Fenn P, Drummond M: Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004;88:1107–1112.
50.
Sharma S, Brown GC, Brown MM, Hollands H, Shah GK: The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051–2059.
51.
Beaumont P, Singerman LJ, Lees M, et al: Economic evaluation of photodynamic therapy with verteporfin for predominantly classic subfoveal CNV secondary to AMD (abstract). Retina 2002 Congr, San Francisco, Sep 28–Oct 2, 2002.
52.
Lees M, Davey PJ, Price N, et al: Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: the case of Australia (abstract No PES6). Value Health 2003;6:239.
53.
Bressler NM, Arnold J, Benchaboune M, et al: Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes – TAP report No 3. Arch Ophthalmol 2002;120:1443–1454.
54.
Rubin GS, Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group: Effects of verteporfin therapy on contrast on sensitivity: results from the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) investigation – TAP report No 4. Retina 2002;22:536–544.
55.
Ruckman J, Green LS, Beeswon J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N: 2′-Fluoropyrimidine RNA-based aptamers to the 165 amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556–20567.
56.
Jager RD, Aiello LP, Patel SC, Cunningham ET Jr: Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676–698.
57.
Mieler W; VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group: Safety evaluation of second year treatment of age-related macular degeneration with pegaptanib sodium (Macugen): VEGF Inhibition Study in Ocular Neovascularization (VISION) (abstract 1380). Assoc Res Vision Ophthalmol annu meet, 2005.
58.
Presta L, Chen H, O’Connor S, Chisholm V, Meng Y, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–4599.
59.
Heier J, Sy J, McCluskey E: RhuFab V2 in wet AMD – 6 month continued improvement following multiple intravitreal injections. Invest Ophthalmol Vis Sci 2003;44:e-abstract 972.
60.
Heier J, Rosenfeld P, Kim R, Butler S, Shams N: Long-term safety of multidose injections of Lucentis (ranibizumab) in neovascular AMD (abstract PO368). Am Acad Ophthalmol annu meet, 2004.
61.
Heier J, Rosenfeld P, Antoszyk A, Hantsbarger G, Kim R, Shams N: Long-term experience with Lucentis (ranibizumab) in patients with neovascular age-related macular degeneration (abstract B162). Assoc Res Vision Ophthalmol annu meet, 2005.
62.
Rosenfeld P, Schwartz S, Blumenkranz M, Miller J, Haller J, Reimann J, Greene W, Shams N: Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048–1053.
63.
Miller JW, Chung CY, Kim R; the MARINA Study Group: Randomised, controlled phase III study of ranibizumab (Lucentis™) for minimally classic or occult neovascular age-related macular degeneration. Am Soc Retina Specialists 23rd Annu Meet, Montreal, July 16–20, 2005.
64.
Fischer S, Renz D, Schaper W, Karliczek G: In vitro effects of dexamethasone on hypoxia-induced hyprepermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 2001;411:231–243.
65.
Lewis GD, Campbell WB, Johnson AR: Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986;119:62–69.
66.
Umland SP, Nahrebne DK, Razac S, Beavis A, Pennline K, Egan R, Billah M: The inhibitor effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997;100:511–519.
67.
Bhattacherjee P, Williams RN, Eakions KE: A comparison of the ocular anti-inflammatory activity of steroidal and nonsteroidal compounds in the rat. Invest Ophthalmol Vis Sci 1983;24:1143–1146.
68.
Ingber DE, Madri JA, Folkman J: A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986;119:1768–1775.
69.
Penfold PL, Wen L, Madigan MC, Gillies M, King N, Provis J: Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for molecular degeneration. Clin Exp Immunol 2000;121:458–465.
70.
Penfold PL, Wen L, Madigan MC, King NJ, Provis JM: Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43:3125–3130.
71.
Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P: Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240:42–48.
72.
Danis RP, Bingaman DP, Yang Y, Ladd B: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099–2104.
73.
Penfold P, Gyory J, Hunyor A, Billson F: Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust NZ J Ophthalmol 1995;23:293–298.
74.
Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone in exudative age-related macular degeneration. Retina 2000;20:244–250.
75.
Gillies MC, Simpson JM, Penfold P, Hunyor ABL, Chua W, Mitchell P, Billson F: A randomised clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macula degeneration: one-year results. Arch Ophthalmol 2003;121:667–673.
76.
Spaide RF, Sorenson J, Maranan L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517–1525.
77.
Spaide R, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301–304.
78.
Chaudhary V, Mao A, Hooper P, Sheidow T: The effect of triamcinolone acetonide as an adjunctive treatment to verteporfin therapy in neovascular age-related macular degeneration: a prospective, randomised, placebo-controlled pilot clinical trial (abstract 2308). Assoc Res Vision Ophthalmol annu meet, 2005.
79.
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor A: Safety of an intravitreal injection of triamcinolone: results from a randomised clinical trial. Arch Ophthalmol 2004;122:336–340.
80.
Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R: Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462–468.
81.
Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24–27.
82.
Nelson ML, Tennant MT, Sivalingam A, Regillo C, Belmont J, Martidis A: Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686–691.
83.
Roth D, Chieh J, Spirn M, Green S, Yarian D, Chaudhry N: Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279–1282.
84.
Sutter F, Gillies M: Psuedo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972–974.
85.
Aiello LP, Brucker AJ, Chang S, Cunningham ETJ, D’Amico DJ, Flynn HW, Grillone L, Hutcherson S, Liebmann J, O’Brien T, Scott I, Spaide R, Ta C, Trese M: Evolving guidelines for intravitreous injections. Retina 2004;24:S3–S19.
86.
Becker B, Bresnick G, Chevrette L: Intraocular pressure and its response to topical corticosteroids in diabetes. Arch Ophthalmol 1966;74:621–624.
87.
Bigger JF, Palmberg PF, Zink H, Becker B: Sensitivity to glucocorticoids in primary open-angle glaucoma. N Engl J Med 1972;287:992.
88.
BenEzra D, Griffin BW, Maftzir G: Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997;38:1962.
89.
Clark AF: AL-3789: a novel ophthalmic angiostatic steroid. Exp Opin Invest Drugs 1997;6:1867–1877.
90.
McNatt LG, Weimer L, Yanni J, Clark AF: Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 1999;15:413–423.
91.
Penn JS, Rajaratnam VS, Collier RJ, Clark AF: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42:283–290.
92.
DeFaller JM, Clark AF: A new pharmacological treatment for angiogenesis; in Taylor HR (ed): Pterygium. The Hague, Kugler Publications, 2000, pp 159–181.
93.
D’Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna S, Robertson S, Russell S, Singerman L, Slakter J, Sullivan E, Yannuzzi L, Zilliox P: Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14–23.
94.
D’Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson S, Russell S, Singerman L, Slakter J, Sullivan E, Yannuzzi L, Zilliox P: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372–2385.
95.
Slakter J, Bochow T, Harper A, Schaffer H, Zilliox P, Robertson S: Evaluation of anecortave acetate 15 mg for depot suspension versus photodynamic therapy with Visudyne for inhibition of choroidal neovascularization in patients with exudative amd: twelve-month clinical outcomes (abstract PA040). Am Acad Ophthalmol annu meet, 2004.
96.
Schmidt-Erfurth U, Michaels S, Michels R, Aue A: Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthamol 2005;15:482–485.
97.
Augustin A, D’Amico D, Mieler W, Schneebaum C, Beasley C: Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005;243:9–12.
98.
Gustavsson C, Agardh E: Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomised pilot study. Acta Ophthalmol Scand 2005;83:148–153.
99.
Reichel E: Results from the TTT4CNV clinical trial. Macula Soc 28th annu meet, 2005.
100.
Frennesson C, Bourghardt Peebo B, Jarkman S, Nilsson S: The effects of photodynamic therapy and transpupillary thermotherapy for the treatment of subfoveal, occult choroidal neovascularization in age-related macular degeneration are compared in a randomised study (abstract B275). Assoc Res Vision Ophthalmol annu meet, 2005.
101.
Tranos P, Wren S, Peter N, Dhir L, Kon C, Rassam S: Effect of transpupillary thermotherapy (TTT) for the treatment of choroidal neovascular membrane (CNV) secondary to age-related macular degeneration (AMD) on patients’ central visual fields (abstract B458). Assoc Res Vision Ophthalmol annu meet, 2005.
102.
Merrill P, LoRusso F, Lomeo M, Saxe S, Khan M, Lambert H: Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 1999;106:782–789.
103.
Lambert HM, Capone AJ, Aaberg TM, Sternberg P, Mandell B, Lopez P: Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992;113:257–262.
104.
Thomas MA, Kaplan HJ: Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1991;111:1–7.
105.
Bressler N, Bressler S, Childs A, Haller J, Hawkins B, Lewis H, MacCumber M, Marsh M, Redford M, Sternberg P, Thomas M, Williams G: Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings – SST report No 13. Ophthalmology 2004;111:1993–2006.
106.
Toth CA, Friedman SF: Macular translocation with 360-degree peripheral retinectomy: impact of technique and surgical experience on visual outcome. Retina 2001;21:293–303.
107.
Postgens H, Bodanowitz S, Kroll P: Low-dose radiation therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1997;235:656–661.
108.
Spaide R, Guyer D, McCormick B, Yannuzzi L, Burke K, Mendelsohn M, Haas A, Slakter J, Sorenson J, Fisher Y, Abramson D: External beam radiation therapy for choroidal neovascularization. Ophthalmology 1998;105:24–30.
109.
Marcus D, Sheils W, Johnson M, McIntosh M, Leibach B, Maguire A, Alexander J, Samy C: External beam radiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomised clinical trial. Arch Ophthalmol 2001;119:171–180.
110.
Hart P, Chakravarthy U, Mackenzie G, Chisholm I, Bird A, Stevenson M, Owens S, Hall V, Houston R, McCulloch D, Plowman N: Visual outcomes in the subfoveal radiotherapy study: a randomised controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol 2002;120:1029–1038.
111.
Chakravarthy U, Houston R, Archer D: Treatment of age-related subfoveal neovascular membranes by telepathy: a pilot study. Br J Ophthalmol 1993;77:265–273.
112.
Berson A, Finger P, Sherr D, Emery R, Alfieri A, Bosworth J: Radiotherapy for age-related macular degeneration: preliminary results of a potentially new treatment. Int J Radiat Oncol Biol Phys 1996;36:861–865.
113.
Sasai K, Murata R, Mandai M: Radiation therapy for ocular choroidal neovascularization (phase I/II study): preliminary report. Int J Radiat Oncol Biol Phys 1997;39:173–178.
114.
Churei H, Ohkubo K, Nakajo M: External beam radiation therapy for age-related macular degeneration: two years’ follow-up results at a total dose of 20 Gy in 10 fractions. Radiat Med 2004;22:398–404.
115.
American Academy of Ophthalmology Retina Panel: Age-related Macular Degeneration 2003. San Francisco, American Academy of Ophthalmology. Preferred Practice Patterns.
116.
Wormald R, Evans J, Smeeth L, Henshaw K: Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2003;2:CD002030.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
